No Data
No Data
Guoyuan Securities: Each overseas business model has its own advantages and disadvantages. Pharmaceutical companies should choose according to their own size.
Leveraging external resources is currently the most mainstream mode for Chinese pharmaceutical companies to expand overseas, which is suitable for companies with limited resources and in need of international experience accumulation, but it also means that the company's voice will be weakened and the relative benefits of sharing will be limited.
Hong Kong stock concept tracking | Innovative drug policy released, medical companies will speed up improvement in the second half of the year (with concept stocks).
Recently, several domestic heavyweight innovative drugs have been approved, and heavyweight data has been successively announced by ASCO, ESMO, ADA, and EHA. The negotiation rules for payment-side medical insurance tend to be clear and mild, and the regulatory side promotes the industry around clinical value. Domestic new drugs have entered the 2.0 era.
Hong Kong stock market concept tracking | Heavy policies supporting the development of innovative drugs are introduced! The industry is expected to enter the fast lane of development (with concept stocks).
On July 5th, the State Council's executive meeting discussed and deployed the work related to promoting high-quality development of the digital economy, and approved the Implementation Plan for Supporting the Development of Innovative Drugs throughout the Whole Chain.
Here's Why We Think Essex Bio-Technology Limited's (HKG:1061) CEO Compensation Looks Fair
A record high! The total number of clinical trials exceeded 4,000 in 2023
According to the report, in 2023, the total number of clinical trials registered on the drug clinical trial registration and information disclosure platform surpassed 4,000 for the first time, reaching 4,300 (in terms of CTR), the highest total number of registrations in history, an increase of 26.1% over the total number of registrations in 2022.
Interpretation of ESG Annual Report|Yisheng Biotechnology (01061) Releases 2023 ESG Report Greenhouse Gas Density Decreased by 33.3% YoY
Zhitong Finance App News. Recently, Yisheng Biotechnology (01061) released the “2023 Environmental, Social and Governance Report”, which sets out the Group's strategies and practices in the three areas of environmental protection, social responsibility and operational governance for the year ended December 31, 2023, covering the business operated by the Group. According to reports, Yisheng Biotechnology is mainly engaged in manufacturing, sales, marketing and distribution of pharmaceuticals, and its main operating area is China. According to the ESG report, the board of directors of Yisheng Biotech bears full responsibility for the company's ESG strategy and ESG report, and is responsible for evaluating and determining ESG-related risks and
No Data
Syuee : Penny stocks are the realm of dreams and nightmares for speculators.
HopeAlways : Penny stocks are speculative in nature, and tend to more volatile; more suited for day trading and those who can stomach higher risks.
HuatEver : I started my trading journey with Penny Storks, well guided by a sharp witted mentor. This “1st pot of gold” has got me “hooked” on to Moomoo’s trading platform.
HuatLadyOP HuatEver: A very auspicious beginning to add to your trading portfolio.
HuatLadyOP HopeAlways: I reckon you have blacklisted penny stocks trading as red flags.
View more comments...